A Phase IIb study of the monoclonal antibody lintuzumab, also known as SGN33, has failed to demonstrate that the experimental drug, in combination with low-dose chemotherapy, is any better than the current combination chemotherapy regimen standard for patients over age 60 with acute myeloid leukemia.
Seattle Genetics, which secured the license to the drug in 2005, told Reuters that based on the disappointing results, they intend to discontinue its development.
Fortunately, the company has in the pipeline one of the more anticipated drugs for hematologic cancers, brentuximab vedotin, also known as SGN35. Data from two recent trials of SGN35 in patients with Hodgkin's lymphoma and anaplastic large cell lymphoma are due out soon.
CANCER TYPE(S)
Acute myeloid leukemia
TREATMENT TYPE(S)
Monoclonal antibody
Source
Reuters
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
